257 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MYL Mylan N.V. $37.22 $19.19B N/A
Article Searches
Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks http://www.zacks.com/stock/news/617525/top-ranked-nasdaq-100-etf-at-new-high-5-best-stocks?cid=CS-ZC-FT-etf_news_and_commentary-617525 Nov 13, 2019 - Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.
Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase http://www.zacks.com/stock/news/610241/teva-teva-q3-earnings-miss-stock-up-on-guidance-increase?cid=CS-ZC-FT-analyst_blog|earnings_article-610241 Nov 08, 2019 - Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
Mylan N.V. (MYL) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/11/05/mylan-nv-myl-q3-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Nov 05, 2019 - MYL earnings call for the period ending September 30, 2019.
Mylan N.V. (MYL) CEO Heather Bresch on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4302872-mylan-n-v-myl-ceo-heather-bresch-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Nov 05, 2019 - Mylan N.V. (NASDAQ:MYL) Q3 2019 Earnings Conference Call November 05, 2019 10:00 AM ET Company Participants Melissa Trombetta - Head, Global Investor Relations Robert Coury - Chairman Heather Bresch -
Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss http://www.zacks.com/stock/news/604734/mylans-myl-q3-earnings-beat-estimates-revenues-miss?cid=CS-ZC-FT-analyst_blog|earnings_article-604734 Nov 05, 2019 - Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More http://www.zacks.com/stock/news/602683/drug-biotech-stocks-nov-5-earnings-roster-agn-regn-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-602683 Nov 04, 2019 - Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy? http://www.zacks.com/stock/news/590740/mylan-myl-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-590740 Oct 29, 2019 - Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View http://www.zacks.com/stock/news/590799/pfizer-pfe-rises-on-q3-earnings-sales-beat-ups-eps-view?cid=CS-ZC-FT-analyst_blog|earnings_article-590799 Oct 29, 2019 - Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.
Acorda (ACOR) to Post Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/582508/acorda-acor-to-post-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-582508 Oct 24, 2019 - During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Why the Earnings Surprise Streak Could Continue for Mylan (MYL) http://www.zacks.com/stock/news/557762/why-the-earnings-surprise-streak-could-continue-for-mylan-myl?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-557762 Oct 10, 2019 - Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pages: 123456...26

Page 1>